Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Curt D Furberg

Showing results (31-40 of 169) with videos related to

Pageof 17
Sort By:
Current Hypertension Reports|November 30, 2014
Plasma renin testing to guide antihypertensive therapyAnthony J Viera, Curt D Furberg
Evidence-Based Cardiovascular Medicine|June 7, 2006
Evaluating professional performance in cardiovascular medicineRobert D Furberg, Curt D Furberg
Circulation|November 26, 2003
Should evidence-based proof of drug efficacy be extrapolated to a "class of agents"?Curt D Furberg, Bruce M Psaty
The American Journal of Geriatric Cardiology|July 1, 1995
Lessons From the Cardiovascular Health Study Question and Answer FormatCurt D. Furberg, Richard M. Steingart
Respiratory Medicine|September 6, 2011
GOLD COPD stage I is not associated with increased risk of deathPhilip H Quanjer, Curt D Furberg
The New England Journal of Medicine|February 17, 2005
COX-2 inhibitors--lessons in drug safetyBruce M Psaty, Curt D Furberg
JAMA|January 17, 2013
Expedited review of new drugs--replyThomas J Moore, Curt D Furberg
JAMA Internal Medicine|October 30, 2013
Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008Thomas J Moore, Curt D Furberg
ACP Journal Club|January 20, 2005
Review: hormone replacement therapy may reduce the risk for death in younger but not older postmenopausal womenCurt D Furberg, Bruce M Psaty
The New England Journal of Medicine|June 7, 2007
The record on rosiglitazone and the risk of myocardial infarctionBruce M Psaty, Curt D Furberg
Pageof 17

Showing results (31-40 of 169) with videos related to

Sort By:
Pageof 17
Current Hypertension Reports|November 30, 2014
Plasma renin testing to guide antihypertensive therapyAnthony J Viera, Curt D Furberg
Evidence-Based Cardiovascular Medicine|June 7, 2006
Evaluating professional performance in cardiovascular medicineRobert D Furberg, Curt D Furberg
Circulation|November 26, 2003
Should evidence-based proof of drug efficacy be extrapolated to a "class of agents"?Curt D Furberg, Bruce M Psaty
The American Journal of Geriatric Cardiology|July 1, 1995
Lessons From the Cardiovascular Health Study Question and Answer FormatCurt D. Furberg, Richard M. Steingart
Respiratory Medicine|September 6, 2011
GOLD COPD stage I is not associated with increased risk of deathPhilip H Quanjer, Curt D Furberg
The New England Journal of Medicine|February 17, 2005
COX-2 inhibitors--lessons in drug safetyBruce M Psaty, Curt D Furberg
JAMA|January 17, 2013
Expedited review of new drugs--replyThomas J Moore, Curt D Furberg
JAMA Internal Medicine|October 30, 2013
Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008Thomas J Moore, Curt D Furberg
ACP Journal Club|January 20, 2005
Review: hormone replacement therapy may reduce the risk for death in younger but not older postmenopausal womenCurt D Furberg, Bruce M Psaty
The New England Journal of Medicine|June 7, 2007
The record on rosiglitazone and the risk of myocardial infarctionBruce M Psaty, Curt D Furberg
Pageof 17